Search
Results
showing 1-10 of 1005
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
June 2026
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.
Years Ahead in HIV Prevention Research: Time to Market
June 2026
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Speeding Up Access to PrEP
June 2026
The timeline for hitting key milestones in product introduction is moving faster for injectable LEN than for any previous PrEP products, starting from the announcement of efficacy results in Phase III trials. LEN’s accelerated timeline compared to oral PrEP, DVR, and CAB reflects a field-wide effort to learn lessons from previous PrEP rollout and not repeat the mistakes of the past.
Advocates’ Primer: Understanding Bioequivalence and Pharmacokinetic Studies in Next-Generation HIV Prevention Products
June 2026
As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.
An Advocates’ Checklist for Lenacapavir for PrEP Introduction
June 2026
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.
What Does It Take to Conduct HIV Cure Research?
May 2026
Progress towards an HIV cure depends on strengthening four critical systems: lab equipment, sustainable funding, policy & programs, and training.
Lenacapavir Regulatory Approval
May 2026
Regulatory approvals, pending decisions, and appeals as of May 2026.
EXPrESSIVE Phase III Program Countries of MK-8527
May 2026
Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.
Analytical Treatment Interruption (ATI)
May 2026
In this video, from the Series of Jojo, viewers are introduced to a methodology used to assess the efficacy of cure strategies — Analytical Treatment Interruption (ATI). Watch to learn more.
showing 1-10 of 1005